Published in N Engl J Med on August 28, 2014
Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med (2014) 4.76
Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease. JAMA (2015) 3.89
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
Cost-Effectiveness of Transcatheter Aortic Valve Replacement With a Self-Expanding Prosthesis Versus Surgical Aortic Valve Replacement. J Am Coll Cardiol (2016) 1.51
Personalizing Colonoscopy Screening for Elderly Individuals Based on Screening History, Cancer Risk, and Comorbidity Status Could Increase Cost Effectiveness. Gastroenterology (2015) 1.50
Current status of cost utility analyses in total joint arthroplasty: a systematic review. Clin Orthop Relat Res (2014) 1.46
Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant (2015) 1.42
Electrocardiographic Screening for Prolonged QT Interval to Reduce Sudden Cardiac Death in Psychiatric Patients: A Cost-Effectiveness Analysis. PLoS One (2015) 1.39
The cost-effectiveness of surgical treatment of medial unicompartmental knee osteoarthritis in younger patients: a computer model-based evaluation. J Bone Joint Surg Am (2015) 1.39
Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. J Clin Oncol (2015) 1.16
Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol (2016) 1.04
Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol (2015) 1.02
Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood (2015) 0.93
Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction (2015) 0.92
Cost-Effectiveness and Public Health Effect of Influenza Vaccine Strategies for U.S. Elderly Adults. J Am Geriatr Soc (2016) 0.87
Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis. Ann Intern Med (2015) 0.87
Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research. Value Health (2016) 0.86
Cost-Effectiveness of Bronchial Thermoplasty, Omalizumab, and Standard Therapy for Moderate-to-Severe Allergic Asthma. PLoS One (2016) 0.85
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C. PLoS One (2015) 0.84
How much does it cost to identify a critically ill child experiencing electrographic seizures? J Clin Neurophysiol (2015) 0.84
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clin Cardiol (2016) 0.83
Cost-Effectiveness of Pertussis Vaccination During Pregnancy in the United States. Am J Epidemiol (2016) 0.83
Performance and Cost-Effectiveness of Computed Tomography Lung Cancer Screening Scenarios in a Population-Based Setting: A Microsimulation Modeling Analysis in Ontario, Canada. PLoS Med (2017) 0.83
Health Aid Is Allocated Efficiently, But Not Optimally: Insights From A Review Of Cost-Effectiveness Studies. Health Aff (Millwood) (2015) 0.82
Cost-Effectiveness of Different Forms of Intra-Articular Injections for the Treatment of Osteoarthritis of the Knee. Adv Ther (2016) 0.82
Showing Value in Newborn Screening: Challenges in Quantifying the Effectiveness and Cost-Effectiveness of Early Detection of Phenylketonuria and Cystic Fibrosis. Healthcare (Basel) (2015) 0.82
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol (2015) 0.82
Long-Term Cost-Effectiveness of Upper Airway Stimulation for the Treatment of Obstructive Sleep Apnea: A Model-Based Projection Based on the STAR Trial. Sleep (2015) 0.82
PCSK9 Inhibitors: A Technology Worth Paying For? Pharmacoeconomics (2016) 0.81
Cost Effectiveness of Influenza Vaccine Choices in Children Aged 2-8 Years in the U.S. Am J Prev Med (2016) 0.81
Cost Utility of Competing Strategies to Prevent Endoscopic Transmission of Carbapenem-Resistant Enterobacteriaceae. Am J Gastroenterol (2015) 0.81
Cost effectiveness of adherence to IDSA/ATS guidelines in elderly patients hospitalized for Community-Aquired Pneumonia. BMC Med Inform Decis Mak (2016) 0.80
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥65 Years With Nonvalvular Atrial Fibrillation. Am J Cardiol (2015) 0.80
POEM is a cost-effective procedure: cost-utility analysis of endoscopic and surgical treatment options in the management of achalasia. Surg Endosc (2016) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Rationality, practice variation and person-centred health policy: a threshold hypothesis. J Eval Clin Pract (2015) 0.79
Cost-effectiveness analysis of pregabalin for treatment of chronic low back pain in patients with accompanying lower limb pain (neuropathic component) in Japan. Clinicoecon Outcomes Res (2015) 0.79
Can delivery systems use cost-effectiveness analysis to reduce healthcare costs and improve value? F1000Res (2016) 0.78
Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circ Cardiovasc Qual Outcomes (2015) 0.78
Health Benefits and Cost-Effectiveness of Asymptomatic Screening for Hypertension and High Cholesterol and Aspirin Counseling for Primary Prevention. Ann Fam Med (2017) 0.78
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer. Br J Cancer (2015) 0.78
Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population. Patient Prefer Adherence (2015) 0.78
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One (2016) 0.78
Detecting Germline PTEN Mutations Among At-Risk Patients With Cancer: An Age- and Sex-Specific Cost-Effectiveness Analysis. J Clin Oncol (2015) 0.78
Realities in cost-effectiveness analyses: a study of castration-resistant prostate cancer patients using a medical claims database. Springerplus (2015) 0.78
Total cost-effectiveness of mammography screening strategies. Health Rep (2015) 0.77
The Cost-Effectiveness of Oral Nutrition Supplementation for Malnourished Older Hospital Patients. Appl Health Econ Health Policy (2017) 0.77
Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center. Lipids Health Dis (2016) 0.77
Evaluating the quality and use of economic data in decisions about essential medicines. Bull World Health Organ (2015) 0.77
Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. Clin Lymphoma Myeloma Leuk (2015) 0.77
Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis. J Thorac Imaging (2015) 0.77
How much will we pay to increase steps per day? Examining the cost-effectiveness of a pedometer-based lifestyle program in primary care. Prev Med Rep (2015) 0.77
Cost-effectiveness of neoadjuvant concurrent chemoradiotherapy versus esophagectomy for locally advanced esophageal squamous cell carcinoma: A population-based matched case-control study. Thorac Cancer (2015) 0.77
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis Cartilage (2015) 0.77
Measurement and comparison of health utility assessments in chronic rhinosinusitis. Int Forum Allergy Rhinol (2015) 0.77
Could EEG Monitoring in Critically Ill Children Be a Cost-effective Neuroprotective Strategy? J Clin Neurophysiol (2015) 0.76
Cost-Effectiveness/Cost-Benefit Analysis of Newborn Screening for Severe Combined Immune Deficiency in Washington State. J Pediatr (2016) 0.76
Targeted Therapies Compared to Dacarbazine for Treatment of BRAF(V600E) Metastatic Melanoma: A Cost-Effectiveness Analysis. J Skin Cancer (2015) 0.76
The Annual Burden of Seasonal Influenza in the US Veterans Affairs Population. PLoS One (2017) 0.76
Toward More Efficient Surveillance of Barrett's Esophagus: Identification and Exclusion of Patients at Low Risk of Cancer. World J Surg (2016) 0.76
Cost-Effectiveness of Field Trauma Triage among Injured Adults Served by Emergency Medical Services. J Am Coll Surg (2016) 0.75
Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke. PLoS One (2016) 0.75
Cost-Effectiveness Analysis of Breast Reconstruction Options in the Setting of Postmastectomy Radiotherapy Using the BREAST-Q. Plast Reconstr Surg (2016) 0.75
Cost effectiveness and value of information analyses of islet cell transplantation in the management of 'unstable' type 1 diabetes mellitus. BMC Endocr Disord (2016) 0.75
A Web-Based Computer-Tailored Alcohol Prevention Program for Adolescents: Cost-Effectiveness and Intersectoral Costs and Benefits. J Med Internet Res (2016) 0.75
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. J Med Econ (2013) 0.75
Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. Oncologist (2015) 0.75
Hitting the Optimal Vaccination Percentage and the Risks of Error: Why to Miss Right. PLoS One (2016) 0.75
Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus. J Natl Cancer Inst (2016) 0.75
Estimating the Population Benefits and Costs of Rituximab Therapy in the United States from 1998 to 2013 Using Real-World Data. Med Care (2016) 0.75
Impact of patient adherence on the cost-effectiveness of noninvasive tests for the initial diagnosis of Helicobacter pylori infection in the United States. Patient Prefer Adherence (2016) 0.75
Cost-effectiveness of preventive case management for parents with a mental illness: a randomized controlled trial from three economic perspectives. BMC Health Serv Res (2016) 0.75
Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug Healthc Patient Saf (2016) 0.75
Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States. PLoS One (2016) 0.75
Adding value to mechanical ventilation. J Bras Pneumol (2014) 0.75
Rethinking cost-effectiveness in the era of zero healthcare spending growth. Int J Equity Health (2016) 0.75
Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. PLoS One (2015) 0.75
Living in a material world: tumor-treating fields at the top of the charts. Neuro Oncol (2016) 0.75
Decision Modeling in Sleep Apnea: The Critical Roles of Pretest Probability, Cost of Untreated Obstructive Sleep Apnea, and Time Horizon. J Clin Sleep Med (2015) 0.75
Prioritizing HIV comparative effectiveness trials based on value of information: generic versus brand-name ART in the US. HIV Clin Trials (2015) 0.75
Cost-effectiveness of spinal manipulative therapy, supervised exercise, and home exercise for older adults with chronic neck pain. Spine J (2016) 0.75
Which BRCA genetic testing programs are ready for implementation in health care? A systematic review of economic evaluations. Genet Med (2016) 0.75
The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. J Virus Erad (2015) 0.75
The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model. Hum Vaccin Immunother (2016) 0.75
Cost-Effectiveness of the 4 Pillars Practice Transformation Program to Improve Vaccination of Adults Aged 65 and Older. J Am Geriatr Soc (2016) 0.75
Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics (2016) 0.75
Comparative effectiveness research for the clinician researcher: a framework for making a methodological design choice. Trials (2016) 0.75
Cost-Utility Analysis: Sartorius Flap versus Negative Pressure Therapy for Infected Vascular Groin Graft Managment. Plast Reconstr Surg Glob Open (2015) 0.75
Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes. Ann Intern Med (2016) 0.75
Cost-Effectiveness of Direct-Acting Anti-viral Treatment in Hepatitis C-infected Liver Transplant Candidates with Compensated Cirrhosis and Hepatocellular Carcinoma. Transplantation (2016) 0.75
An Economic Analysis of Strategies to Control Clostridium Difficile Transmission and Infection Using an Agent-Based Simulation Model. PLoS One (2016) 0.75
Screening and Treatment for Subclinical Hypertensive Heart Disease in Emergency Department Patients With Uncontrolled Blood Pressure: A Cost Effectiveness Analysis. Acad Emerg Med (2016) 0.75
A review of the clinical utility of duloxetine in the treatment of diabetic peripheral neuropathic pain. Ther Clin Risk Manag (2015) 0.75
Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. Lipids Health Dis (2017) 0.75
Clinical and Economic Evaluation of Treatment Strategies for T1N0 Anal Canal Cancer. Am J Clin Oncol (2016) 0.75
Cost-effectiveness of SHINE: A Telephone Translation of the Diabetes Prevention Program. Health Serv Insights (2016) 0.75
Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast Cancer Res Treat (2016) 0.75
Contrasting Medical and Legal Standards of Evidence: A Precision Medicine Case Study. J Law Med Ethics (2016) 0.75
Cost effectiveness of routine duodenal biopsies in iron deficiency anemia. World J Gastroenterol (2016) 0.75
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Medicare and cost-effectiveness analysis. N Engl J Med (2005) 4.20
Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis. Lancet (2006) 3.60
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA (2003) 3.25
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst (2004) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Impact of referral patterns on the use of chemotherapy for lung cancer. J Clin Oncol (2002) 3.09
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol (2011) 2.83
HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med (2005) 2.60
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med (2003) 2.48
Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis (2005) 2.47
Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making (2007) 2.46
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Estimating long-term effectiveness of lung cancer screening in the Mayo CT screening study. Radiology (2008) 2.37
Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med (2006) 2.28
A quantitative analysis of fish consumption and coronary heart disease mortality. Am J Prev Med (2005) 2.27
Costs and benefits of targeted screening for causes of sudden cardiac death in children and adolescents. Circulation (2012) 2.24
Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med (2009) 2.13
The global cost of nonoptimal blood pressure. J Hypertens (2009) 2.00
Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making (2002) 1.94
Measuring the Value of Prescription Drugs. N Engl J Med (2015) 1.91
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making (2012) 1.81
Cost-effectiveness analysis of hypertension guidelines in South Africa: absolute risk versus blood pressure level. Circulation (2005) 1.80
Health economic evaluations: the special case of end-stage renal disease treatment. Med Decis Making (2002) 1.78
Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health (2012) 1.76
Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis (2007) 1.70
Cost effectiveness of thromboprophylaxis with a low-molecular-weight heparin versus unfractionated heparin in acutely ill medical inpatients. Am J Manag Care (2004) 1.69
Legislating against use of cost-effectiveness information. N Engl J Med (2010) 1.68
The cost effectiveness of gonorrhea screening in urban emergency departments. Sex Transm Dis (2005) 1.64
The lifetime medical cost savings from preventing HIV in the United States. Med Care (2015) 1.61
Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr (2010) 1.57
Potential risks and benefits of HIV treatment simplification: a simulation model of a proposed clinical trial. Clin Infect Dis (2007) 1.57
Routine human immunodeficiency virus testing: an economic evaluation of current guidelines. Am J Med (2005) 1.56
Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS (2015) 1.49
Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health (2008) 1.48
Outcomes and costs of acute treatment of traumatic brain injury. J Trauma (2002) 1.44
The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis (2007) 1.43
Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ (2010) 1.43
Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm (2012) 1.41
Much cheaper, almost as good: decrementally cost-effective medical innovation. Ann Intern Med (2009) 1.40
A quantitative analysis of fish consumption and stroke risk. Am J Prev Med (2005) 1.39
Uncertainty and patient heterogeneity in medical decision models. Med Decis Making (2010) 1.38
Cost-effectiveness of coronary MDCT in the triage of patients with acute chest pain. AJR Am J Roentgenol (2008) 1.37
Comparative effectiveness evidence from the spine patient outcomes research trial: surgical versus nonoperative care for spinal stenosis, degenerative spondylolisthesis, and intervertebral disc herniation. Spine (Phila Pa 1976) (2011) 1.36
Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS (2007) 1.34
Clinical outcomes and cost-effectiveness of coronary computed tomography angiography in the evaluation of patients with chest pain. J Am Coll Cardiol (2009) 1.34
Screening for sudden cardiac death in the young: report from a national heart, lung, and blood institute working group. Circulation (2011) 1.30
A systematic review of the evidence concerning the economic impact of employee-focused health promotion and wellness programs. J Occup Environ Med (2013) 1.30
HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. AIDS (2007) 1.30
Economic model of a birth cohort screening program for hepatitis C virus. Hepatology (2012) 1.28
Optimal allocation of testing dollars: the example of HIV counseling, testing, and referral. Med Decis Making (2005) 1.28
Adopting helical CT screening for lung cancer: potential health consequences during a 15-year period. Cancer (2008) 1.26
Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol (2002) 1.26
How much are Americans willing to pay for a quality-adjusted life year? Med Care (2008) 1.26
Economic burden of childhood autism spectrum disorders. Pediatrics (2014) 1.26
Comparative effectiveness: asking the right questions, choosing the right method. Health Aff (Millwood) (2005) 1.25
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults. Arch Intern Med (2002) 1.21
Population-level changes in folate intake by age, gender, and race/ethnicity after folic acid fortification. Am J Public Health (2006) 1.17
Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. Health Econ (2006) 1.14
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ (2004) 1.14
Projected cost-effectiveness of smoking cessation interventions in patients hospitalized with myocardial infarction. Arch Intern Med (2011) 1.14
Treatment for primary HIV infection: projecting outcomes of immediate, interrupted, or delayed therapy. J Acquir Immune Defic Syndr (2002) 1.13
Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis. Radiology (2008) 1.13
Unintended benefits: the potential economic impact of addressing risk factors to prevent Alzheimer's disease. Health Aff (Millwood) (2014) 1.13
Annual financial impact of well-differentiated thyroid cancer care in the United States. Cancer (2014) 1.13
Measuring the costs of outreach motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women. BMC Pregnancy Childbirth (2009) 1.12
When is evidence sufficient? Health Aff (Millwood) (2005) 1.12
30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement. Pharmacoeconomics (2009) 1.12
A comparative assessment of non-laboratory-based versus commonly used laboratory-based cardiovascular disease risk scores in the NHANES III population. PLoS One (2011) 1.11
Monitoring of antiretroviral therapy in low-resource settings. Lancet (2008) 1.11
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines. Arch Intern Med (2002) 1.11
Cost-effectiveness of motivational interviewing for smoking cessation and relapse prevention among low-income pregnant women: a randomized controlled trial. Value Health (2007) 1.09
Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity. AIDS (2008) 1.09
Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension. J Am Coll Cardiol (2012) 1.08
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health (2007) 1.06
Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening. Risk Anal (2012) 1.05
Toward modernizing the systematic review pipeline in genetics: efficient updating via data mining. Genet Med (2012) 1.04
Lifetime cost of HIV care in France during the era of highly active antiretroviral therapy. Antivir Ther (2002) 1.04
Health trade-offs from policies to alter fish consumption. Am J Prev Med (2005) 1.04
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. AIDS (2012) 1.03
Electrocardiogram screening for disorders that cause sudden cardiac death in asymptomatic children: a meta-analysis. Pediatrics (2012) 1.02
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. Value Health (2004) 1.02
More americans living longer with cardiovascular disease will increase costs while lowering quality of life. Health Aff (Millwood) (2013) 1.01
Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler (2003) 1.01
Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J (2007) 1.01
Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer (2007) 1.01